scholarly journals Immune Response Among the Children to Hepatitis B Vaccination: A Community-based Study in Bangladesh

2018 ◽  
Vol 44 (2) ◽  
pp. 103-108
Author(s):  
Mohammad Monir Hossain ◽  
Ahmed Nawsher Alam ◽  
Mahmuda Siddiqua ◽  
Ayesha Siddika ◽  
Afzalun Nessa
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Protective Efficacy ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Breakthrough Infection ◽  
Protective Level ◽  
Hbv Vaccine ◽  
Public Health Burden

Hepatitis B virus infection is a vaccine preventable infection of liver which remains a key public health burden globally. The development of Anti-HBs titre greater than or equal to 10 IU/L is considered as protective immunity and any titre less than 10 IU/L as non-protective following HBV vaccination. There is no comprehensive and authentic data regarding the immune response even 10 years after the integration of the HBV vaccine in to the EPI programme in Bangladesh and specifically, in Brahmonbaria district. The study was also aimed to assess the long term immune response among HBV vaccinated children. Blood sample from 500 vaccinated children were tested for Anti-HBs, and anti-HBc. Sero negative children were given 1 dose of HBV vaccine as a booster. Samples from booster vaccine were taken one month later and tested for anti Hbs titre. Anti HBs titre was found below protective level in about 46.0% (230/500) participants. Sero-protection rate decreased to 72.2% in 5 to 6 years age group which further decreased to 58.3% in 7 to 9 years age group and increased again to 69.5% in 10 to 12 years age group children. On the other hand, the mean anti Hbs titre was 97.72 IU/L initially and then increased with the increasing of age from 165.40 IU/L to 196.67 IU/L. Breakthrough infection of HBV was seen in 1.2% (6/500) participants measuring by anti HBc which indicated protective efficacy of HBV vaccine was about 98.8% (494/500). Sero negative participants were given a booster dose; 93.6% (131/140) participants showed boosting of mean anti HBs titre upto 804.92 IU/L which was below protective level (<10 IU/L) before booster dose. Anti-HBs titre goes below with the increase of age after vaccination. Most of the participants had immunological memory which will boost antibody titre after any exposure, so routine booster dose is not needed. But non-responder to vaccination should screen after primary vaccination because of chance of breakthrough infection.

scholarly journals STUDY OF IMMUNE RESPONSE AFTER HEPATITIS B VACCINATION IN DOCTORS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
B.L. Meena ◽  
Nikhil Gandhi ◽  
M.P. Sharma
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Seroprotection Rate

Background: Aim of our study was to evaluate the immune response after hepatitis B vaccination and to determine the duration of protective levels of HBsAb titre in doctors. From our study we concluded that hepatitis-B vaccine gives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required in immunocompetent persons after primary vaccination. Method: In this study total 100 doctors of our institution were included who were vaccinated against hepatitis B. Data were obtained regarding age, sex, weight, height, BMI and duration of vaccination period. Doctors with no prior vaccination or incomplete vaccination or those who took booster vaccination were excluded from this study. Results: The mean titre was observed to be higher in 30 to 34 years of age group (584.42±4.03.21) as compared to age group of less than 25 and greater than 40 years. Moreover, males were observed to have higher mean titre as compared to females. (411.64± 417.27 vs 333.66± 431.49) but not statistically significant.  Similar with age and sex, duration of vaccination status was also not statistically significant. When we compared the  duration of vaccination status with  age group , mean titre was more in ≥30 years of age group as compared to <30 years (younger age groups) but statistically significant relation was observed only with the 1 month to <5 years of duration. Conclusion: From our study we concluded that hepatitis-B vaccinegives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required inimmuno-competent persons after primary vaccination. Keywords: HbsAg titre , HepatitsB vaccine , seroprotection rate.

scholarly journals Review of Hepatitis B Vaccination in Children of Workers of an Oil & Gas Industry in Lho'seumawe and Lho'sukon, North Aceh

2018 ◽  
Vol 34 (7-8) ◽  
pp. 209-15
Author(s):  
Chairul Adillah Harahap ◽  
Sari Leyli Harahap ◽  
Chairuddin P. Lubis ◽  
Ahmad Judin
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Medical Records ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Gas Industry ◽  
The Third ◽  
Hepatitis B Vaccines ◽  
Fourth Dose ◽  
Oil Gas

We describe a retrospective study on hepatitis-B immunization in the Indonesian workers' children of Mobil-Oil Indonesia Lho' Seumawe and Lho'sukon, North Aceh. Data were obtained from medical records and included all children in the 0-15 years age group who had been immunized against hepatitis B types and schedules of vaccines, pre-immunization seromarkers, and anti HBsAb after the third immunization were recorded. For hundred and twenty children had received three doses of,hepatitis B vaccines; 180 children had them at 0, 1 and 2 months and the rest at 0, 1 and 6 months. Type of vaccine used was hunian plasma derived vaccine with a dosage of 5 µg per shot All of them (except the newborns) were tested and had seromarkers negative to hepatitis 8 infection prior to immunization. Testing for immune response (HBsAb) 2-6 months after the third immunization could only be done in 213 children, where 168 (78.9%) showed HBsAb titer> 10 miU/ml, 5 (2,30Al) had HBsAb < 10 miU/ml, and the remaining 40 (18,8%) showed no seroconversion. Of those 40 children who did not seroconversed, 31 were given a fourth dose, and 14 children were retested for their HBsAb titre. Seven children had positive responses and the rest remained negative.

scholarly journals Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

1970 ◽  
Vol 10 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Md Abdul Ahad ◽  
Md Abdul Alim ◽  
Abhijit Guho ◽  
Quazi Tarikul Islam ◽  
Khan Abul Kalam Azad
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals.   doi: 10.3329/jom.v10i2.2817 J MEDICINE 2009; 10 : 67-76

scholarly journals Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 227
Author(s):  
Rosa Papadopoli ◽  
Caterina De Sarro ◽  
Carlo Torti ◽  
Claudia Pileggi ◽  
Maria Pavia
Keyword(s):  
Immune Response ◽  
Booster Dose ◽  
Immunological Response ◽  
Hepatitis B Vaccination ◽  
Anamnestic Response ◽  
Hbv Vaccine ◽  
Vaccine Booster ◽  
Study Population ◽  
Healthcare Professions ◽  
Medical And Healthcare

Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier. The study population consisted of vaccinated students attending medical and healthcare professions schools. A booster dose was offered to subjects with a <10 mIU/mL anti-HBs titer. The post-booster anti-HBs titer was evaluated after four weeks. The subjects with a <10 mIU/mL post-booster anti-HBs titer, received a second and third dose of the vaccine and after one month they were retested. A <10 mIU/mL anti-HBs titer was found in 35.1% of the participants and 92.2% of subjects that were boosted had a ≥10 mIU/mL post-booster anti-HBs titer, whereas 7.8% did not mount an anamnestic response. A low post-booster response (10–100 mIU/mL anti-HBs) was significantly more likely in subjects with a <2.00 mIU/mL pre-booster titer compared to those with a 2.00–9.99 mIU/mL pre-booster titer. The anamnestic response was significantly related to the baseline anti-HBs levels. A booster dose of the HBV vaccine may be insufficient to induce an immunological response in subjects with undetectable anti-HBs titers. A booster dose might be implemented when an anamnestic response is still present.

scholarly journals Is There any Difference in Antibody Titer Between Children and Adults after Recombinant Hepatitis B Vaccination?

1970 ◽  
Vol 21 (1) ◽  
pp. 1-11
Author(s):  
M Abdul Ahad ◽  
M Abdul Alim ◽  
Abhiji Guho ◽  
ARM Saifuddin Ekram
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antibody Titer ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (≥10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and nonresponders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals. Vaccinated individuals from lower socioeconomic condition have had comparatively low rate of protective antibody than people from middle and upper classes. Recombinant HB vaccine induces good level of protective immunity among vaccinated persons. The present study showed that the proportion of adults (93.33%) developed level of protective antibody titer was higher than that of children (83.33%). It indicates that there is difference of antibody titer between children and adults after recombinant Hepatitis B vaccination.    doi: 10.3329/taj.v21i1.3210 TAJ 2008; 21(1): 1-11

Effect of Oral Levamisole Supplementation to Hepatitis B Vaccination on the Rate of Immune Response in Chronic Hemodialysis Patients

Nephron ◽  
2000 ◽  
Vol 84 (3) ◽  
pp. 291-292 ◽  
Author(s):  
M. Deniz Ayli ◽  
Cüneyt Ensari ◽  
Meltem Ayli ◽  
Fahri Mandiroglu ◽  
Suat Mut
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Hepatitis B Vaccination

scholarly journals Hepatitis B vaccination status and vaccine immune response among children in rural Senegal

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
L Perieres ◽  
M Coste ◽  
S Ndiour ◽  
P Halfon ◽  
C Sokhna ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Chronic Infection ◽  
Vaccination Status ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Chronic Hbv Infection ◽  
Hbv Vaccination ◽  
Chronic Hbv ◽  
Vaccine Immunity

Abstract Background Hepatitis B vaccination during childhood is key to reduce the prevalence of Hepatitis B virus (HBV) infection. In Senegal, a highly endemic country, the three-dose hepatitis B vaccine and the birth dose vaccine were introduced in the Expanded Programme on Immunization (EPI) in 2004 and 2016 respectively. This study aimed to determine chronic HBV infection prevalence, hepatitis B vaccination status and vaccine immunity among children in Senegal. Methods A cross-sectional study including HBV screening was conducted at home among children aged 6 months to 15 years (i.e. born after the introduction of the HBV vaccine in the EPI) in the rural zone of Niakhar. Dried Blood Spot (DBS) samples were collected for the detection of HBsAg, anti-HBc Ab and anti-HBs Ab using chemoluminescence. Vaccination status was assessed using information on vaccination cards. Detectable vaccine immunity was defined with an adjusted DBS threshold of DOI≥0.36 IU/mL (corresponding to 10 IU/mL in venous blood sampling). Results Between October and December 2018, 455 children were enrolled. Preliminary results show that 7/455 (1.5%) had been in contact with HBV (positive anti-HBc Ab) and 5/455 (1.1%) had chronic HBV infection (positive HBsAg). Only 161/455 (35.4%) children had a vaccination card available. Among those, 150/161 (93.2%) received at least 3 doses of hepatitis B vaccine, of which 83/150 (55.3%) had detectable vaccine immunity. The proportion of children with detectable vaccine immunity was significantly higher in children &lt;5 years than in children aged 5-9 and 10-15 (72.3% versus 47.3%, p = 0.006 and 72.3% versus 14.3%, p &lt; 0.001). Conclusions Preliminary results suggest a low prevalence of HBV chronic infection among children born after the introduction of HBV vaccination in Senegal. However, detectable vaccine immunity rapidly decreases with age among vaccinated children, signalling a need for further studies on the immune response to HBV vaccination in this context. Key messages HBV chronic infection is low among children born after the introduction of HBV vaccination in Senegal. Further studies on the immune response to HBV vaccination in this context are needed.

Sign in / Sign up

Export Citation Format

Share Document